WMS 2023 poster presentation: Ataluren slows the decline of muscle function in patients with nmDMD: A meta-analysis of three randomized, double-blind, placebo-controlled trials
This poster presentation, as part of WMS 2023, explores the effects of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) across 3 clinical trials
Explore how the patient demographics and characteristics varied across the trials
Compare the efficacy of ataluren against placebo treatments in nmDMD
Discover how treatment with ataluren impacted the 6-minute walk distance (6MWD) outcomes in patients with nmDMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster presentation was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300184 | January 2024
Sign in or register to access exclusive content on this site